Media headlines about Stellar Biotechnologies (NASDAQ:SBOT) have been trending somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stellar Biotechnologies earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.8203857994438 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of Stellar Biotechnologies traded down $0.02, reaching $2.24, during mid-day trading on Friday, according to Marketbeat. The company had a trading volume of 263,508 shares, compared to its average volume of 168,483. The firm has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.65 and a beta of 0.43. Stellar Biotechnologies has a 12-month low of $2.12 and a 12-month high of $10.85.
Separately, ValuEngine lowered shares of Stellar Biotechnologies from a “hold” rating to a “sell” rating in a research report on Monday, May 14th.
Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.
Receive News & Ratings for Stellar Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.